Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My heavy problem is I can't buy through my broker at this level I mean through fidelity i don't to be left out, though I some at higher prices
Ryan Schadel
?
@CRyanSchadel
Following
Following @CRyanSchadel
More
$LTNC sales budget for May is a whopping $766k. We need to get these new branches online ASAP or risk falling behind come June/July.
From Ryan: LTNC April revenue came in at $584k. This is actually $4k LOWER than our budgeted sales of $588k. While I can point to this or that as the reasons why, I would just be making excuses for missing the mark. We can do better.
unlimited shares? Then keep buying them.
Form 4, form 3, Form SC 13G Filed today...
Then, give him your money..
CEO and the company looking at licensing tech to other established companies around the world. Great news.
CEO Frank J. Kristan I hope our dearest CEO still in charge it is being investment of over 5 years now, at least we deserves some concrete updates.
Conversion Labs Announces PDF Simpli Achieves Milestone of Over 1 Million Registered Users
Download as PDF
May 01, 2019
NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (CVLB) (“Conversion Labs” or “Company”), an e-commerce company focused on building and scaling innovative branded consumer products, today announced that the Company’s majority owned subsidiary, LegalSimpli Software LLC, achieved a milestone of over 1 million registered users of its PDF Simpli software product.
PDF Simpli, accessible at www.pdfsimpli.com, is a software as a service product that allows users to easily edit, convert, compress, split, or compress PDF files. Conversion Labs acquired 51% of Legal Simpli Software LLC in June of 2018. Since its investment, PDF Simpli has grown from approximately 10,000 registrants to more than 1 million. PDF Simpli is presently ranked in the top 50,000 websites globally and is marketed in more than 100 countries around the world.
"The phenomenal growth of registered and subscribed users within our first year shows the size of the PDF market and that it is ripe for disruption. I cannot be more pleased with the performance year to date and see significant growth and revenue potential for the remainder of 2019 and beyond," stated Sean Fitzpatrick, CEO & President of LegalSimpli Software LLC. "This first Software as a Service business from Conversion Labs continues to complement the extensive physical product offerings, while increasing margin growth into the future.”
About Conversion Labs
Conversion Labs, Inc. (the "Company") is an e-commerce company with a portfolio of innovative and proprietary brands. Conversion Labs’ scalable and global advertising technology infrastructure leverages the world’s largest social media, search and e-commerce platforms (Facebook, Google & Amazon) to rapidly grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.conversionlabs.com or email us at info@conversionlabs.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause Conversion Labs, Inc.’s actual results to differ materially from those anticipated by the forward-looking statements. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell its products; the expected benefits and efficacy of the Company's products; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC.
Source: Conversion Labs, Inc.
Released May 1, 2019
That is your opinion not binding, you loss somewhere and gain somewhere. If this turn around now I believe you will be one of the cheerleaders. wasting time here all in the name of protecting others make no sense. I still believe things can turn around but not advocating for any one to buy. The company will show results then other things will follow, that all I am saying brother. Been here for years like you waiting.
Apple to release earning today after our let see what they have for Pixel mags inc.
You are about right but we just want this to work out so we can get something out of money and time invested here. All these antagonistic postures will not benefit anyone and that is a fact.
Ryan Tweet:
Save the date: May 31, 2019. I'll be livestreaming the annual $LTNC update via our YouTube channel. More details soon.
We need to be sensible about our collective plight, the ridiculous to say the least
WHERE IS COMING FROM AND TO WHERE?
News out!
Endonovo Therapeutics Provides Corporate Update
BY GlobeNewswire
— 8:00 AM ET 04/26/2019
LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics ( ENDV
Loading...
Loading...
), Inc. ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019.
Revenue projections for the first quarter ended March 31, 2019 are expected to increase by roughly 80% over the same quarter last year. Revenue for the quarter will exceed $40,000, as compared to $22,173 during the same period in the prior year.
Alan Collier, Endonovo’s Chief Executive Officer, stated “I am pleased to announce Endonovo continues to execute our business plan and strategy implemented after acquiring the PEMF assets and technology. During the first quarter of 2019, we have grown our sales network of numerous independent sales reps and distributors throughout the United States. These efforts have contributed to the increased revenues realized during the first quarter and anticipate only further growing in the future. We look forward to issuing the first quarter financial and operating results which will provide greater details very soon.”
“The opioid epidemic is one of the foremost issues in society today, all of which allows SofPulse to provide an alternative in post-operative pain management,” continued Mr. Collier. “In addition to the partnerships and getting into a second hospital, the first quarter has been productive to us from better understanding our market, initiating new business opportunities and expanding our workforce. The sales numbers and business accomplishments throughout the first quarter are a direct reflection of our partners and, as such, we are expanding our human capital in anticipation of what we believe will result in a vastly successful national roll-out.”
About Endonovo Therapeutics ( ENDV
Loading...
Loading...
)
Endonovo Therapeutics, Inc. ( ENDV
Loading...
Loading...
) is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics ( ENDV
Loading...
Loading...
), Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Image: Logo.jpg
Just take position look promising, Positive cash flow.
Wow! over 9.2 billions outstanding shares, where is the way forward?
NITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 10, 2019
TAUTACHROME INC.
(Exact name of registrant as specified in its charter)
Delaware
333-141907
20-5034780
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1846 E. Innovation Park Drive, Oro Valley, Arizona
85755
(Address of principal executive offices)
(Zip Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
Tautachrome will begin a free distribution of a portion of its KLK20 cryptotokens (the “Distribution Tokens”) to certain Tautachrome shareholders on Friday March 15, 2019. KLK20 tokens are ERC20 compliant tokens living on the Ethereum blockchain. Our tokens have been determined by the SEC to be securities requiring registration prior to their sale to the public. Promissory notes convertible to our tokens are currently being offered in an SEC-compliant private presale (at http://klickzie.io) under exemption from or exclusion from registration. The Distribution Tokens will be distributed pro-rata among the Shareholders of Record (those shareholders who were of record on the Record Date, namely the date Tuesday 1/16/18 announced in early January last year). Instructions for Shareholders of Record to claim and receive their KLK20 tokens will be provided in a future 8K and/or posted on our token sale site at http://klickzie.io. The distribution will occur over a period of time expected to be 30 to 60 days in duration.
The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for any purpose and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of an general incorporation language in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TAUTACHROME INC.
Date: January 11, 2019
/s/ Jon N. Leonard
Jon N. Leonard
President & CEO
3
News out Form 8K filled.
Here, see this from Tweeter account
Easy As ABC_Labor Smart $LTNC To Be Scooped Up In All Cash Transaction By Unnamed Nasdaq Traded Company, Official PR Coming As Soon As Wednesday
(link: https://rumormurmursbuzz.blogspot.com/2019/01/easy-as-abclabor-smart-ltnc-to-be.html)
rumormurmursbuzz.blogspot.com/2019/01/easy-a…
It is time to roll, been here for more than 4 years I think we deserves some pay back on our investment, let encourage the CEO to do the right thing fast instead of offensive attacked on hourly/daily bases. I Put more than $8g here, Still believe something positive will come out of this. Mr. Ryan if you are reading this go current so I can average down more. Can't buy now through fidelity. Expressing opinion only.
Hope this is the beginning of what we have been waiting for folks.
Endonovo Expands SofPulse Commercialization
BY GlobeNewswire
— 9:20 AM ET 12/13/2018
LOS ANGELES, CA, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics ( ENDV
Loading...
), Inc. ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the commercialization and further advancement of its proprietary product – SofPulse®.
Alan Collier, CEO of Endonovo Therapeutics ( ENDV
Loading...
), stated, “We are pleased to announce the positive performance of our SofPulse® units which have been delivered and utilized to date. The Company has received numerous calls and emails from medical professionals and patients alike, detailing the beneficial results stemming from the use of SofPulse®. We believe this performance further reinforces and validates the commercial maturity of SofPulse® while demonstrating the capacity to address medical issues without patients being prescribed and dependent on opioids.”
The company his initiated additional sales and marketing strategies to ensure future growth:
The company is in the process of hiring an independent sales force; and
Management is pleased with the ongoing efforts as related to an agreement recently announced with US Authentic Trading Company to handle distribution throughout hospitals in China. We anticipate definitive agreements to be executed in the first quarter of 2019.
“As we conclude 2018, we primarily needed to focus on retaining ownership of SofPulse®. We are pleased to announce we successfully paid the balance of the purchase price of the SofPulse® technology due to the former owners. Additionally, we have successfully established significant sales and distribution agreements and partnerships, where we are now well poised to focus and execute on our new sales initiatives entering 2019,” commented Mr. Collier. “Our sales and marketing strategies are now being implemented globally as we enter a significantly broader commercialization of SofPulse®.”
About Endonovo Therapeutics ( ENDV
Loading...
)
Endonovo Therapeutics, Inc. ( ENDV
Loading...
) is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics ( ENDV
Loading...
), Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Image: Logo.jpg
News about commercialization out!
sorry 1 :15000
It is sad to adapt this ratio 1 for 150000?
Bayside Corporation Files for 1 For 15,000 Reverse Split
Press Release | 11/30/2018
WESTON, FL / ACCESSWIRE / November 30, 2018 / Bayside Corporation (OTC PINK: BYSD); ("Bayside" or the "Company") is pleased to announce that today the Company has filed with the State of Wyoming and FINRA its intention to do a reverse stock split with a ratio of 1 for 15,000, expected to be effective on December 29, 2018. The split, which was approved by the Board and shareholders, will have no inherent effect or change on the Company's value or total market capitalization.
"This action is part of our larger plan to increase shareholder value. This year, under our new management team, the company has not only become current with all its financial filings and held its first shareholder meeting in years, but also did what we said we were going to do -- executed on our business plan to deploy a network of Bitcoin ATMs throughout the country. We have seen sustained revenue growth and expect it to continue in the coming year," commented Justin Frankel, Chief Executive Officer of Bayside Corporate.
Frankel added, "While we've seen improvements in virtually all areas of our business, our share price has remained low and stagnate. Stocks that are priced more accurately attract more attention from market analysts, financial media and larger investors. We are one of a small group of pure-play, revenue generating, publicly traded companies operating in the blockchain and crypto asset space today. The growth of blockchain technology and the continued maturity of the crypto-asset market will continue to present exciting opportunities for us, and a higher stock price will allow us to better take advantage of these opportunities."
The Shareholders previously approved a split of up to 1 for 20 at the shareholder meeting June 19, 2018. Subsequent to the shareholder meeting, the Board determined that a larger reverse was necessary. On November 12, 2019 the Board and a majority of the shares entitled to vote on the matter voted to set the reverse ratio at 1 for 15,000.
Steven Hoffman, Chairman of Bayside Corporation, stated, "The Board believes that undertaking this reverse split is in the best long-term interest of all shareholders. Over the past year, the company has ensured its filing are current and has seen revenue from operations continue to grow. This is not a potentially dilutive measure for Bayside, rather it is a way to get the public markets to better recognize what we have accomplished thus far and allow us to take advantage of the explosive growth in the blockchain industry."
To viewthe Company's disclosures, click here.
About BaysideCorp
Bayside Corp. is an American corporation that trades publicly under the symbol "BYSD". At Bayside Corp., we believe that emerging technologies will create new opportunities for generations to come. Crypto-assets and blockchain technology will fundamentally impact a broad range of industries such as financial services, digital rights management, and computer processing and programming, along with many others. Our goal is to become the premier provider of infrastructure in this new and exciting industry. For additional information on the Company visit our website at: http://www.baysidecorp.com.
Forward-Looking Statements:
This press release maycontain projections and other forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of theSecurities Act of 1934, as amended, and are made pursuant to the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Any suchprojections or statement reflect the company's current views with respect tofuture events and financial performance. No assurances can be given, however,that these events will occur or that such projections will be achieved and thatactual results could differ materially from those projected. Important factorsthat could cause actual results to differ from those projected are decreases inoil and gas prices or decreases in oil and gas production. The company's actualresults could differ materially from those discussed herein. Forward-lookingstatements are subject to risks and uncertainties, including, but not limitedto, government regulation, taxation, spending, competition, general economicconditions and other risk factors which could cause actual results to differ materiallyfrom those projected or implied in the forward-looking statements.
Company Contact:
Info@baysidecorp.com
SOURCE: Bayside Corp.
Minimal five bucks? please don't kill before Monday.
Helios & Matheson Seeks Shareholder Ok for 1-for-500 Reverse Stock Split
BY MT Newswires
— 2:21 PM ET 09/17/2018
02:21 PM EDT, 09/17/2018 (MT Newswires) -- Helios & Matheson Analytics ( HMNY Loading...) , owner of MoviePass, said in a regulatory filing on Monday it plans to ask permission from its shareholders for a one-time reverse stock split of its common stock in a ratio of 1 share-for-2 shares up to a ratio of 1 share-for-500 shares.
A special meeting of shareholders is due to be held on Oct. 18.
The company enacted a 1-for-250 reverse stock split in July.
Helios shares were trading at $0.015, down 30%, at 2:15 pm ET in New York on Monday.
Price: 0.02, Change: -0.01, Percent Change: -29.91
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Shareholders OK? when?
Over 4 years wasted, money lost... double trouble
who is buying all these shares, something is not add up, please enlighten me
Are we finally on the match?
drmicro still here and very active who want to loose out. People still there is values in this.
When are the common shareholders will see anything positive. Reading opinion and comments for more than three years is killing. I think it is high time we know our faith be it good or bad and we can move on, the heaven will not fall. But keep shifting dates does not augur well for anyone. IMHO.
Keep some brother you never know.
Why total assets is still $4.5millions with all with been doing? Somebody help me please.
Are we in a cult or what? Someone help me.
The CEO hint above ongoing revenue, check the last updates paragraph 7:
Michael Goodman has recognized sales as a powerful vehicle for creating change by choice and relationships by intention, not just for increasing commerce, but for making a difference in all walks of life. “The arrival of Michael Goodman opens a new chapter for BioNovelus ( ONOV Loading...
), strongly geared towards sales and creating ongoing revenues as we have moved out of the start-up phase,” says Jean Ekobo, President of BioNovelus ( ONOV Loading...). “For a couple of years, Michael has been following our progress from a distance, and we are happy that he has decided to jump on board now as we focus on distribution and sales, and we needed a sales expert like him.
We are hooked, break pads and rotors rusting unabated. Corrosion continua.